WebDisclosure WebDisclosure
Basculer en Français
9888 Companies
199049 Keywords
129984 Articles
105813 Press releases
Headlines Articles Press releases Lindis Blood Care GmbH Remove
  1. Home
  2. Companies
  3. Lindis Blood Care GmbH
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/11/2024 at 14:05, 1 year 10 months ago

    Lindis Blood Care dévoilera les résultats de l'étude REMOVE sur CATUVAB® lors du symposium NATA24

    CATUVAB® Soins Du Sang Lindis SUPPRIMER L'étude Symposium NATA24 Chirurgie Du Cancer
  • PRESS RELEASE

    published on 04/11/2024 at 14:00, 1 year 10 months ago

    Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium

    Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB at NATA24 Annual Symposium in Bologna, Italy. Prof. Dr. med. Patrick Meybohm to present safety and efficacy data
    Lindis Blood Care CATUVAB NATA24 Annual Symposium Clinical Certification Study Tumor Cells
    Logo of Lindis Blood Care GmbH
Previous page
1 2
Accesswire
  • Published on 02/18/2026 at 19:10, 1 hour 41 minutes ago

    Secure Blockchain Announces Definitive Agreement to Acquire Agentic Solutions Limited, Private Placement and Debt Settlement

  • Published on 02/18/2026 at 15:15, 5 hours 36 minutes ago

    Host of "The Schaftlein Report" on Patriot.TV Delivers Urgent Warning to Trump: 2026 Midterm Course Correction Needed Now

  • Published on 02/18/2026 at 15:00, 5 hours 51 minutes ago

    Jaguar Health Announces a Special One-time Stock Dividend

  • Published on 02/18/2026 at 14:25, 6 hours 26 minutes ago

    Mako Mining Announces Amended and Restated Definitive Agreements for Restructure of Mt. Hamilton Acquisition Consideration and Filing of Supplement to Management Information Circular

  • Published on 02/18/2026 at 14:00, 6 hours 51 minutes ago

    Revolve Achieves Key Interconnection Milestone On 130 MW "El 24 Wind Project" In Mexico

View all ACCESSWIRE
EQS Group
  • Published on 02/18/2026 at 19:11, 1 hour 39 minutes ago

    flatexDEGIRO adopts new capital allocation policy – increase in annual dividend by a factor of seven planned; 2025 guidance slightly exceeded

  • Published on 02/18/2026 at 19:08, 1 hour 42 minutes ago

    POS-Transaction in Own Shares

  • Published on 02/18/2026 at 18:54, 1 hour 56 minutes ago

    EQS-Adhoc: flatexDEGIRO SE: Management and Supervisory Board adopt new capital allocation policy; dividend increase to 20% of Net Income targeted; FY 2025 guidance slightly exceeded

  • Published on 02/18/2026 at 18:21, 2 hours 29 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 02/18/2026 at 18:00, 2 hours 51 minutes ago

    E-PANGO : Décision du Tribunal administratif de Paris en date du 16 février 2026

View all EQS
Les Echos
  • Published on 02/18/2026 at 18:00, 2 hours 51 minutes ago

    Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 janvier 2026

  • Published on 02/18/2026 at 18:00, 2 hours 51 minutes ago

    Outstanding Shares and Voting Rights Statement at 31 January 2026

  • Published on 02/18/2026 at 17:45, 3 hours 6 minutes ago

    Chiffre d'affaires annuelle

  • Published on 02/18/2026 at 17:40, 3 hours 11 minutes ago

    GROUPE ES - Communiqué sur les résultats 2025

  • Published on 02/18/2026 at 13:45, 7 hours 5 minutes ago

    NRJ GROUP - Non renouvellement Licence FM Nationale NRJ Suède

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy